Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics, operating within the healthcare and biotechnology sector. The company entered the public markets in 2023 through the completion of a SPAC business combination, trading under the ticker ABP. On December 12, 2023, Abpro filed an 8-K with the Securities and Exchange Commission, reflecting a material corporate disclosure during its post-merger phase. As a de-SPAC entity, ABP represents the cohort of biopharmaceutical companies that have transitioned through blank-check vehicle structures into publicly traded operational firms. For complete filing histories, deal timelines, and real-time data on ABP and the broader SPAC universe, sign up for full access at SpacDesk.